October 2024 ASX Penny Stocks To Watch

In This Article:

The Australian market is experiencing a cautious sentiment, with the ASX200 set to decline following mixed performances on Wall Street. Amid these fluctuations, investors often seek opportunities that can offer growth potential despite broader market uncertainties. Penny stocks, though an outdated term, remain relevant as they represent smaller or newer companies that might provide surprising value when backed by strong financial health.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

LaserBond (ASX:LBL)

A$0.555

A$65.06M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.805

A$128.44M

★★★★☆☆

MaxiPARTS (ASX:MXI)

A$1.895

A$104.82M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.50

A$310.07M

★★★★★☆

Helloworld Travel (ASX:HLO)

A$1.865

A$300.41M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.72

A$842.94M

★★★★★☆

West African Resources (ASX:WAF)

A$1.71

A$1.95B

★★★★★★

Atlas Pearls (ASX:ATP)

A$0.13

A$56.64M

★★★★★★

GTN (ASX:GTN)

A$0.47

A$92.11M

★★★★★★

Joyce (ASX:JYC)

A$3.93

A$115.92M

★★★★★★

Click here to see the full list of 1,026 stocks from our ASX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Little Green Pharma

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Little Green Pharma Ltd is involved in the cultivation, production, and distribution of medicinal cannabis products both in Australia and internationally, with a market cap of A$48.28 million.

Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to A$25.63 million.

Market Cap: A$48.28M

Little Green Pharma Ltd, with a market cap of A$48.28 million, operates in the medicinal cannabis sector and generates revenue primarily from its Pharmaceuticals segment amounting to A$25.63 million. Despite being unprofitable with a negative return on equity of -10.55%, the company has more cash than total debt and sufficient cash runway for over three years based on current free cash flow. Its short-term assets exceed both short- and long-term liabilities, providing some financial stability. The stock is trading at good value compared to peers but remains highly volatile with stable weekly volatility over the past year.

ASX:LGP Revenue & Expenses Breakdown as at Oct 2024
ASX:LGP Revenue & Expenses Breakdown as at Oct 2024

Lunnon Metals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Lunnon Metals Limited is engaged in the exploration and development of nickel and gold in Australia, with a market cap of A$74.96 million.

Operations: The company's revenue is primarily derived from mineral exploration, amounting to A$0.001551 million.